ORIGINAL RESEARCH Inducing Apoptosis and Suppressing Inflammatory Reactions in Synovial Fibroblasts are Two Important Ways for Guizhi-Shaoyao-Zhimu **Decoction Against Rheumatoid Arthritis**

> This article was published in the following Dove Press journal: Journal of Inflammation Research

Background and Objectives: Guizhi-Shaoyao-Zhimu decoction (GSZD) is often applied to control rheumatoid arthritis (RA), gout, osteoarthritis, etc. In this study, bioinformatic analysis and experimental verification were used to uncover the integral mechanism profile of GSZD against RA.

Materials and Methods: The chemical compositions of GSZD were identified by UPLC-QTOF-MS/MS. MH7A cell model was established to screen active compounds in GSZD, and potential targets of these compounds were predicted through online database retrieval. The differential expression genes (DEGs) in synovial tissue of RA patients and normal controls were retrieved from the GEO database. DEGs and the predicated compounds targets were overlapped, and the overlapped genes were subsequently enriched by GO and KEGG analysis. The pathways with significant enrichments were further experimentally verified.

Results: A total of 19 constituents were identified from GSZD, and 11 compounds showed obviously antiproliferative effects on MH7A cells with $IC_{50} < 100 \ \mu g/mL$. Bioinformatic analysis indicated that IL-1β, IL-6, MAPK8, JAK2, CXCL8, and CASP3 were the main targets of GSZD, and the integral pharmacological mechanisms profile of GSZD might be related to anti-inflammation and proapoptosis. GSZD can promote the loss of mitochondrial membrane potential (MOMP) and induce apoptosis in MH7A cells. Furthermore, in vitro experiments showed GSZD can not only downregulate mRNA expressions of IL-18 (p < 0.05), IL-6 (p < 0.05), MMPs (p < 0.05) and CCL5 (p < 0.05) but also inhibit the nuclear transcription of NF- κ B. GSZD also reduced the expressions of Bcl-2 (p<0.05), JAK2 (p < 0.05), STAT-3 (p < 0.05), whereas increase Bax (p < 0.05), Caspase-3 (p < 0.05) and caspase-9 (p<0.05).

Conclusion: Collectively, inducing synovial fibroblast apoptosis and inhibiting inflammatory response are two important ways for GSZD to RA, and our study proved bioinformatic analysis combined with experimental verification is a feasible method to explore the drug targets and mechanism of actions of TCMs.

Keywords: apoptosis, anti-inflammatory, bioinformatic analysis, rheumatoid arthritis, Guizhi-Shaoyao-Zhimu decoction

Introduction

As a chronic invasive autoimmune disease, rheumatoid arthritis (RA) is characterized by joint involvement, proliferative synovitis and bone and cartilage destruction. Currently, the pathological mechanisms of RA are not clear. However, the rheumatoid arthritis

217

Journal of Inflammation Research 2021:14 217-236

© 2021 Zhang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. bp and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission foro Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Qing Zhang¹ Hu-Xinyue Duan¹ Ruo-Lan Li¹ Jia-Yi Sun² lia Liu¹ Wei Peng¹ Chun-Jie Wu Yong-Xiang Gao³

¹School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, People's Republic of China; ²Innovation Research Institute, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, People's Republic of China; ³School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, People's Republic of China

Correspondence: Chun-Jie Wu School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People's Republic of China Tel +86-28-61801001 Email wucjcdtcm@163.com

Yong-Xiang Gao School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, People's Republic of China Tel +86-28-61801001 Email gaoyxcdtcm@126.com



fibroblast-like synovial cells (RA-FLSs) are generally believed to be one of the main causes of RA.¹ Previous scientific researchers have confirmed that RA-FLSs could release excessive pro-inflammatory cytokines, chemokine, and matrix metalloproteinase (MMP), resulting in synovial hyperplasia, inflammatory reactions, pannus formation and bone and cartilage destruction. In addition, the activated RA-FLSs possess the tumor-like abnormal proliferation without inadequate apoptosis.¹ Apoptosis, also known as programmed cell death, is an important form of cell death, which is of great significance to the growth and development of the organism. In addition, the study found that apoptosis did not cause inflammation in the surrounding environment. Consequently, effective induction of apoptosis in RA-FLSs appears to be a feasible method for the control and treatment of RA. Furthermore, increasing evidence has suggested that natural herbal medicines are a good resource when searching for new available candidate drugs for treating RA and its related diseases, in particular the traditional Chinese medicines (TCMs) and their clinically proven recipes.^{2–4}

As is well-known, TCMs and their formulations have good therapeutic effects on many diseases, but their features of "multiple components act on multiple targets and multiple pathways" bring great difficulties to reveal their potential mechanisms.⁵ Network pharmacology is a novel way for investigation of active ingredients, pharmacological mechanism, drug targets of TCMs and TCM formulas.⁵ Furthermore, network pharmacology can explain the mechanism of drug action from a holistic perspective, which coincides with the holistic thinking of TCM theory. Currently, systematical biology is widely applied to study the mechanisms of pathological action of various diseases. In addition, microarray assays and bioinformatic study were comprehensively carried out to analyze the differentially expressed genes (DEGs) under diseases and enrichment functional terms.⁶ In our present study, we aimed to uncover the possible molecular mechanisms of Guizhi-Shaoyao-Zhimu decoction (GSZD) for treating RA using an integrated approach based on network pharmacology, bioinformatics and vivo experiments.

Materials and Methods Chemicals, Reagents, and Materials

Reference substances including malic acid, citric acid, gallic acid, ephedrine, pseudoephedrine, neomangiferin, mangiferin, albiflorin, paeoniflorin, prim-O-glucosylcimifugin, liquiritin, 5-O- β -D-glucosyl-5-O-methylcisamminol, anemarsaponin

E1, anemarsaponin BII, liquiritigenin, anemarsaponin C, licorice saponin G2, glycyrrhizic acid and anemarspaonin I were acquired from the Chengdu Desite Co. Ltd (Chengdu, China), and the purity of these compounds was ≥98%. Annexin V-FITC/PI assay kit was obtained from Multisciences (Lianke) Biotechnology Corporate Limited (Hangzhou, China). CCK8 detection kit and JC-1 probe was obtained from US Everbright®Inc (Suzhou, China). Enhanced chemiluminescence (ECL) luminescence reagent was purchased from Beijing 4A Biotech Co (Beijing, China). NF-kB activity assay kits were purchased from Beyotime Biotech (Haimen, China), and the human tumor necrosis factor (TNF)- α was obtained from Pepro Tech (Rocky Hill, NJ, China). BCA protein quantitative kit and primary antibodies for JAK2, STAT3, Bcl-2, Bax were bought from BOSTER biological technology company (Wuhan, China). C-caspase-9, C-caspase-3, p-JNK1/2, JNK1/2, β-actin, and the IgG-HRP were obtained from Cell Signaling technology (Chivoda-ku, Tokyo, Japan). The OuickEasy[™] Cell Direct RT-qPCR Kit-SYBR Green I kit was obtained from Chengdu Foregene Company Limited.

Prepare the GSZD Extracts

According to the previous method to prepare the freezedried powder of GSZD extract.² Briefly, the nine herbs including Cinnamomi ramulus (12g), Paeoniae radix alba (9 g), Glycyrrhizae radix et rhizoma (6 g), Ephedrae herba (6 g), Zingiberis rhizoma recens (15 g), Atractylodis macrocephalae rhizoma (15)g), Anemarrhenae rhizoma (12 g), Saposhnikoviae radix (12 g), and processed Aconiti lateralis radix praeparata (6 g) are mixed with purified water and soaked for half an hour, then boiled for an hour. Filtrate was collected, vacuum-concentrated at 60°C, and finally freeze-dried to obtain the freeze-dried powder of GSZD water extract. The powder was stored in a dryer for subsequent testing.

Qualitative UPLC-QTOF-MS/MS Analysis

The main chemical composition of GSZD water extract was analyzed by UPLC-QTOF-MS. Chromatographic separation was carried out applying an Agilent 1290 system (Santa Clara, CA, USA). The XBridge BEH C_{18} (2.1×100 mm, i.d.; 2.5 µm, Waters, MA, USA) was applied for sample separation at 45°C using a gradient elution. Acetonitrile (A) and 0.1% formic acid-water (B) were used as mobile phase.

The gradient program was set as: 0–0.2 min, 3% A; 0.2–1.5 min, 3%-10% B; 1.5–2.2 min, 10% A; 2.2–2.9

min, 10–15% A; 2.9–3.3 min, 15% A; 3.3–4.2 min, 15–22% A; 4.2–4.6 min, 22–25% A; 4.6–5.4 min, 25–35% A; 5.4–8.0 min, 35–40% A; 8.0–10.0 min, 40–45% A; 10.0–11.0 min, 45% A; 11.0–13.0 min, 45–3% A. The flow rate and injection volume were set as 0.4 mL/min and 1.0 μ L, respectively. Mass analysis was performed on the 6538 UHD Accurate-Mass Q-TOF LC-MS (Agilent Technologies Inc, Santa Clara, CA, USA) equipped with electrospray ionization (ESI). Nitrogen was applied as auxiliary gas and sheath gas with the flow rate of 12 L/min. The mass determination was carried out based on positive and negative scanning mode with the m/z ranging from 100 to 1000.

Cell Culture

MH7A cells are a novel immortalized rheumatoid fibroblast-like synoviocyte (FLS) line established by Miyazawa et al in 1998, which have highly consistent pathological characteristics with parental FLSs.⁷ At present, MH7A cells as a mature pathological model cells have been widely used in the study of RA.^{2,8,9} Human rheumatoid arthritis fibroblast-like synovial cell line of MH7A was obtained from the Beina Biological Company (Beijing, China), sub-cultured in DMEM (high glucose) containing 10% FBS at 37°C. Cells were passed through every 3–4 days, and only 3–5 generations of MH7A cells were used in the experiment.

Preliminary Screening of Anti-RA Compounds in GSZD

To screen the possible active constituents against RA in GSZD, we used cell counting kit-8 (CCK8) method to detect the effects of the main compounds in GSZD on MH7A cell viability.¹⁰ Briefly, MH7A cells (5×10^3 /well) suspension was placed in 96-well plates and cultured for 24 h. After this, as previously described, the compound at different concentrations (0–100 µg/mL) was used to intervene in the cells for 24 h. At the end of treatment, 20 µL CCK8 was added into the cell culture wells and cultured for another half hour. The OD value of the 96-well plate was recorded at 450 nm by a microporous counter plate and the cell viability of each group was calculated.

Data Collection and Data Preprocessing To Establish GSZD Compound Target Library

All the chemical structures of the screened active compounds by CCK8 assays were drawn by ChemDraw professional 15.0 and saved as Mol. format files, and the Mol. format files of potential active compounds were imported into the PharmMapper (<u>http://www.lilab-ecust.cn/pharm</u><u>mapper/</u>) and SwissTargetPrediction (<u>http://www.swisstar</u><u>getprediction.ch/</u>) online databases to forecast the action targets. Targets of these compounds were collected through high-throughput screening and reverse docking. In addition, compound target libraries were also supplemented the reported targets of GSZD in previous literature.^{11–19}

To Establish RA Targets Library

As a common data platform, the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/ geo) allows open access to gene expression data of arrays, chips and microarrays. We focused only on the comparison of gene expression data sets between synovial tissue samples from patients with RA and normal synovial tissue. At the same time, in order to ensure the stability and credibility of the analysis results, only data sets with a sample size larger than 10 were selected. Finally, the three data sets of RA were downloaded from the GEO database, dataset GSE55457 performed on the (HG-U133A) Affymetrix Human Genome U133A Array (GPL96 platform), and in this gene expression dataset, synovial tissue samples from 13 RA patients and 10 healthy human samples were included, dataset GSE55235 performed on the (HG-U133A) Affymetrix Human Genome U133A Array (GPL96 platform), and in this gene expression dataset, synovial tissue samples from 10 RA patients and 10 healthy human samples (control) were included, dataset GSE1919 performed on the (HG-

U95A) Affymetrix Human Genome U95A Array (GPL91 platform), and in this gene expression dataset, synovial tissue samples from five RA patients and five healthy human samples were included.

The data sets downloaded from the GEO library are imported into the R language (3.6.3), and according to the relevant annotation information on the platform, the probes are transformed into corresponding gene symbols. In the case of a gene symbol with multiple probes, the average value is taken as the final expression value. At the same time, the data is preprocessed by background correction, quantile normalization, base 2 logarithm conversions and so on, and finally the difference analysis of gene expression between normal human and RA patients was realized. In this study, logFC (fold change) \geq 2 and adjusted *p*-values <0.01 considered that the difference was statistically significant, and the corresponding genes were identified as DEGs, combining these DEGs is the RA target library. In addition, some important targets reported in previous literatures regarding the treatment of GSZD on RA are also supplemented in the RA target library.^{2,20–22}

Protein-Protein Interaction (PPI)

The overlapping genes (OGs) obtained from the intersection of RA target library and compound target library are the objective targets of this study. The protein-protein interaction (PPI) analysis of the OGs was performed using the search tool for the retrieval of interacting genes/proteins (STRING) online database (<u>http://string.</u> <u>embl.de/</u>). Furthermore, Cytoscape software (3.6.0) was used to visualize these interactions and construct PPI network diagram. Each node in the diagram represents a target, and the edge represents the interrelationships between targets. In addition, cytoHubba tool was used to analyze the hub genes in PPI.

Construct Drug-Target Network Diagram (DTN)

Collected target compound data pairs were introduce into Cytoscape software to construct drug-target network diagram (DTN). In this network chart, nodes show compounds and proteins, while edges show the interrelationships between compounds and proteins. In addition, the average shortest path length, betweenness centrality, closeness centrality, degree, and other network topology parameters in DTN were analyzed to evaluate the importance of each node in the network graph.

Bioinformatic Analysis

In order to comprehensively analyze the basic functions and participating pathways of these OGs, gene ontology (GO) term function annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were employed with the Clusterprofiler package in R language. P<0.05 was considered statistically significant in this study.

Detection of the Activity of Transcription Factor NF- κB

The cells were inoculated in laser confocal plates $(1 \times 10^4/\text{well})$ and treated with TNF- α (20 ng/mL) and GSZD (0.8, 1.6, 3.2 mg/mL) for 24 h. Subsequently, immunofluorescence staining was performed, following the detailed instruction of the commercial kit, to determine the activation and transfer of the primary NF- κ B subunit p65 to the nucleus under a laser confocal microscope. The NF- κ B P65 staining shows red fluorescence, and the DAPI staining of the nucleus shows blue fluorescence.

qRT-PCR Analysis

The cells were inoculated in a six-well plate (2×105/well) and treated with TNF- α (20 ng/mL) and GSZD (0.8, 1.6, 3.2 mg/mL) for 24 h, and the PCR experiment was conducted according to the previously established experimental method. The total RNA of the cells was extracted with the QuickEasyTM Cell Direct RT-qPCR Kit-SYBR Green I kit according the standard steps in the instructions of kit, the cDNA was synthesized using Direct RT Mix in the kit, and the Direct qPCR Mix-SYBR of kit was used to amplify cDNA, and the primers used in this qRT-PCR test were shown in Table 1.^{23–28} The 2^{- $\Delta\Delta$ ct} method was applied to analyze the mRNA expressions of target genes.²⁹

Flow Cytometry Analysis

The cells were inoculated in a six-well plate $(2 \times 10^5/\text{well})$ and treated with different concentrations of GSZD (0.8, 1.6, 3.2 mg/mL) for 24 h. After treatment, the cells were collected and washed with PBS. Following the standard steps of the instructions of commercial kit, cells were resuspended with 500 µL binding buffer, and stained with 5 µL of annexin V-FITC and PI at 37°C in dark for 30 min. Finally, the cell apoptosis rate was detected by flow cytometry (BD Company, Franklin Lakes, NY, USA).

Mitochondrial Membrane Potential (MOMP) Detection

The decrease of mitochondrial membrane potential (MOMP, $\Delta \Psi$ m) occurred before phosphorylated serine ectropion and activation of caspase hydrolase, which is an important marker of early cell apoptosis. JC-1 is a fluorescent probe that can reflect MOMP changes in cells. In normal condition, JC-1 commonly gathers in the mitochondrial matrix in the form of polymers with red fluorescence under 590 nm. With the reduced MOMP, the JC-1 would exist as monomer with green fluorescence at 530 nm. Therefore, compared with normal cells, the fluorescence intensity ratio of red/green in apoptotic or necrotic cells was reduced. The cells were inoculated in laser confocal plates (1×10⁴/well) and treated with different concentrations of GSZD (0.8, 1.6, 3.2 mg/mL) for 24

Genes		Sequences	Reference
h ILIβ	F R	5'-CCAGGGACAGGTATGGAGCA-3' 5'-TTCAACACGCAGGACAGGTACAG-3'	23
h IL6	F R	5'-AAGCCAGAGCTGTGCAGATGAGTA-3' 5'-TGTCCTGCAGCCACTGGTTC-3'	23
h IL8	F R	5'-AGG GTT GCC AGA TGC AAT AC-3' 5'-AAA CCA AGG CAC AGT GGA AC-3'	24
h MMPI	F R	5'-CTCAATTTCACTTCTGTTTTCTG-3' 5'-CATCTCTGTCGGCAAATTCGT-3'	25
h MMP2	F R	5'-GGATCCGCAAGTGGTCCGTGTGAAGTAT-3' 5'-AAGCTTGCTGTACCCTTGGTCAGGGCAGAA- 3'	26
h MMP3	F R	5'-GAAGACTTTCCAGGGATTGACT-3' 5'-GTGCCTTCTACTACTCTTTCAAC –3'	27
h CCL5	F R	5'- CTACTCGGGAGGCTAAGGCAGGAA –3' 5'- GAGGGGTTGAGACGGCGGAAGC –3'	28
h GAPDH	F R	5'-TGAACGGGAAGCTCACTGG-3' 5'-TCCACCACCCTGTTGCTGTA-3'	27

Table	I.	Sequences	of	Primers	Used	for	aRT-PCR
labic		Jequences	U.	111111111111	Oseu	101	

Abbreviations: F, forward; R, reverse.

h. After treatment, an appropriate amount of JC-1 probe was added to the laser confocal plate and incubated in dark for 20 min. Laser confocal microscopy was used to observe the intensity of red and green fluorescence in cells at 530 nm and 590 nm, and the intensity ratio of red/green was photographed and calculated.

Western Blotting (WB) Assay

The cells were treated in the same way as described before. In short, the cells were inoculated in six-well plates $(2 \times 10^5$ /well) and incubated for 12 h, followed by different concentrations of GSZD (0.8, 1.6, 3.2 mg/mL) and/or TNF- α (20 ng/mL) for 24 h. At the end of the treatment, 100 µL RIPA cell lysate were added to extract the total cell protein. Then, the SDS-PAGE was used to separate the protein, and the separated protein was transferred to polyvinylidene fluoride (PVDF) membrane. Then, 3% BSA/ Tris buffered saline-Tween-20 (TBS-T) buffer was applied to block the PVDF membrane (two hours), and then the PVDF membrane was probed with primary antibodies of JAK2 (dilution of 1:300), STAT3 (dilution of 1:300), Bcl-2 (dilution of 1:300), Bax (dilution of 1:300), C-caspase-9 (dilution of 1:1000), C-caspase-3 (dilution of 1:1000), p-JNK1/2 (dilution of 1:1000), and JNK1/2 (dilution of 1:1000) at 4°C for overnight and then incubated with

HPR-conjugated antibody at 37°C for one hour. Finally, enhanced ECL solution was used to develop the protein bands and record the images, and β -actin was used as the internal reference. Image J software was used to conduct normalized analysis and processing of the collected protein bands.

Statistical Analysis

Each experiment was repeated three times, and the data were expressed as the average of the results of the three experiments. Results were expressed as mean \pm SD. Significant differences between means were compared using the Duncan's multi-range test with the *p*-value <0.05.

Results

Chemical Composition of GSZD Extract

The main components in extracts of GSZD were analyzed qualitatively based on UPLC-QTOF-MS/MS. The analysis results were shown in the Figure 1 and Table 2, including the total ion chromatogram of UPLC-QTOF-MS, as well as the structural formula of main chemical components in GSZD.

Within 13 min, the UPLC-QTOF-MS system detected more than 20 major component peaks from the GSZD




Figure I Result of the HPLC-Q-TOF-MS/MS analysis of the water extracts of GSZD. (A) MS-BPC spectrogram (positive and negative mode). (B) Compounds in water extracts of GSZD identified by the HPLC-Q-TOF-MS/MS assays.

water extract. By comparing with the known chemical constituents in GSZD established by us (a total of 1200 compounds; data are not shown) and the reported literature data,^{30–35} 19 main compounds were finally identified and deduced according to their mass spectrometry behavior and fragment ion characteristics. Finally, by comparing these components with the compound standard reference, the 19 main compounds were identified to be malic acid

(1), citric acid (2), gallic acid (3), ephedrine (4), pseudoephedrine (5), neomangiferin (6), mangiferin (7), albiflorin (8), paeoniflorin (9), prim-O-glucosyl-cimifugin (10), liquiritin (11), 5-O- β -D-glucosyl-5-O-methylcisamminol (12), anemarsaponin E1 (13), anemarsaponin BII (14), liquiritigenin (15), anemarsaponin C (16), licorice saponin G2 (17), glycyrrhizic acid (18), anemarsaponin I (19) respectively. Interestingly, these 19 monomers have been

No.	Compound Name	t _R /min	Molecular Formula	[м-н]⁻	[M+H]⁺	MS/MS m/z
GZ-I	Malic acid	0.731	C ₄ H ₆ O ₅	133.0659		
GZ-2	Citric acid	0.944	C ₆ H ₈ O ₇	191.0201		
GZ-3	Gallic acid	1.363	C ₇ H ₆ O ₅	169.0141		125, 97
GZ-4	Ephedrine	1.791	C ₁₀ H ₁₅ NO		166.0867	148, 132, 115
GZ-5	Pseudoephedrine	2.126	C ₁₀ H ₁₅ NO		166.1232	148
GZ-6	Neomangiferin	2.678	C ₂₅ H ₂₈ O ₁₆	583.1322		565, 493, 463, 421, 331, 301
GZ-7	Mangiferin	3.656	C ₁₉ H ₁₈ O ₁₁	421.0794		331, 301, 285, 271, 259
GZ-8	Albiflorin	4.141	C ₂₃ H ₂₈ O ₁₁	525.1630 [M+HCOO] ⁻		479 [M-H] ⁻ , 435, 357, 327
GZ-9	Paeoniflorin	4.461	C ₂₃ H ₂₈ O ₁₁	525.1621		499, 327, 283, 121
GZ-10	Prim-O-glucosyl-cimifugin	4.577	C ₂₂ H ₂₈ O ₁₁		469.1723	451, 307, 289, 259
GZ-11	Liquiritin	4.971	C ₂₁ H ₂₂ O ₉	417.1204		255, 135, 119, 91
GZ-12	5-O-β-D-glucosyl-5-O- methylcisamminol	5.439	C ₂₂ H ₂₈ O ₁₀		453.1773	291, 273, 259, 243, 219, 205
GZ-13	Anemarsaponin El	5.521	C ₄₅ H ₇₆ O ₂₀	935.4867		773, 756, 612, 594
GZ-14	Anemarsaponin BII	5.965	C ₄₅ H ₇₆ O ₁₉	919.4926		757, 595, 577, 329
GZ-15	Liquiritigenin	6.187	C ₁₅ H ₁₂ O ₄	255.0599		135, 119, 91
GZ-16	Anemarsaponin C	6.713	C ₄₅ H ₇₄ O ₁₈	901.4812		739, 577
GZ-17	Licoricesaponin G2	6.869	C ₄₂ H ₆₂ O ₁₇	837.3906		351, 193, 175
GZ-18	Glycyrrhizic acid	8.085	C ₄₂ H ₆₂ O ₁₆	821.3981		759, 645, 469, 351, 193
GZ-19	Anemarsaponin I	8.249	C ₃₉ H ₆₆ O ₁₄	757.4373		434

Table 2 Precursor and Product lons of Constituents in Guizhi-Shaoyao-Zhimu Decoction

described in the previous literature on GSZD. Among these monomers, compounds 13, 14, 16, 17, 18, and 19 are triterpenoid saponins and steroidal saponins, and followed by flavonoids (including 6, 7, 11, and 15), and the diterpenes (including compounds 8 and 9) and phenylpropanoids (including 10 and 12). Besides, there are three organic acid (compounds 1–3) and two alkaloids (compounds 4 and 5).

Target Prediction of GSZD Against RA

Complete the experiment of this study according to the flow chart in Figure 2A. In short, the effects of 19 compounds in GSZD on the growth activity of MH7A cells were detected by CCK8 experiment. Results as shown in Figure 3, 11 compounds including anemarsaponin I, gallic acid, paeoniflorin could significantly inhibit the activity of cells, suggesting that these compounds are the potential material basis for GSZD to play an anti-RA role. Subsequently, the targets of these compounds were predicted by means of reverse docking, supplemented by literature mining, and 653 targets of GSZD were finally obtained.

After normalization of three data sets (GSE55457, GSE55235, and GSE1919) downloaded from the GEO database, the volcano map and hot spot map of gene expression were obtained (Figure 2B and C). Finally, 549 differentially expressed genes were obtained in the synovial tissue of RA patients and normal controls, among which 237 genes were upregulated and 312 genes were downregulated. At the same time, existing studies have shown that GSZD can play a role in RA treatment by regulating the expression of *JAK2*, CASPA3, *BAX*, *BCL2* and other genes or proteins.^{2,16–18} Therefore, these targets are also taken into account in the construction of RA target library.




Figure 2 Flowchart of the study strategy and overlapped targets screen. (A) Flowchart of the analysis strategy in the study. (B) The volcano plot of the differentially expressed genes in microarray data sets of GSE55457, GSE55235, and GSE1919. The vertical axis represents log 2 FC (fold change) and the horizontal axis represents log 10 (*p*-value). (C) Heatmap of differentially expressed genes (DEGs) in microarray data sets of GSE 55457, GSE55235, and GSE1919. The vertical axis represents be anyle. The horizontal axis represents DEGs. (D) Overlap of the genes by DEGs and predicted targets. Magenta circle is the predictive gene of 11 potential active compounds in GSZD (653), the blue circle is the DEGs in synovial tissue of RA patients and normal patients (574), and the overlap in the middle is the overlapping genes between the two genes (83). (E) PPI network of the screened targets. (F) The top 20 hub genes in the PPI network were selected according to the node degree.

Finally, the RA target library containing 574 genes was obtained. In the end, the intersection of the target of the compound and the target of RA was taken to obtain 83 potential targets (OGs) of GSZD for anti-RA (Figure 2D).

Results of PPI Analysis

The PPI network of GSZD anti-RA target gene was constructed by STRING database. The analysis results showed that many target genes had interaction relationships (Figure 2E), and the top 20 hub genes were selected according to node degree, namely *IL6*, *TNF*, *MAPK8*, *JUN*, *MYC*, *CXCL8*, *CASP3*, *EGFR*, *IL1B*, *HSP90AA1*, *STAT1*, *CCL5*, *JAK2*, *NFKB1*, *CD40*, *PTPRC*, *NFKBIA*, *AR*, *CASP9*, *IL17A*. Among them, *IL6*, *TNF*, *MAPK8*, *CXCL8*, *CASP3*, etc, showed high degree, suggesting these genes might be the potential drug targets of GSZD (Figure 2F).

KEGG and GO Enrichment Analyses of OGs

In order to analyze the biological classification of OGs, functional and pathway enrichment analysis was performed using Clusterprofiler toolkit in R language. The analysis results showed that the accumulation of these OGs into biological processes (BPs) were mainly in response to lipopolysaccharide, positive regulation of cytokine production, leukocyte proliferation, cellular response to biotic stimulus, multicellular organismal homeostasis. The main concentration of the molecular functions (MFs) were the cytokine receptor binding, hormone binding, cytokine activity, ubiquitin like protein ligase binding, protein tyrosine kinase activity, growth factor receptor binding, cysteine-type endopeptidase activity involved in the apoptotic process. Enriched cellular components (CCs) mainly include membrane raft, membrane microdomain, membrane region, external side of plasma membrane, nuclear envelope (Figure 4 and Table 3).

Enrichment analysis of KEGG pathway found that these OGs are mainly concentrated in the apoptosis, IL-17 signaling pathway, MAPK signaling pathway, NF- κ B signaling pathway, RA, Toll-like receptor signaling pathway, the advanced glycation endproducts (AGE)—receptor of advanced glycation endproducts (RAGE) signaling pathway in diabetic complications, TNF signaling pathway (Figure 5 and Table 4). It is undeniable that inflammation plays an important role in the process of autoimmune diseases such




Figure 3 Effects of the main constituents in GSZD on proliferation of MH7A cells. Data were expressed as mean ±SD (n=3).

as RA, and how to effectively control inflammation is also the feasible direction for the development of anti-RA drugs at present.^{30,36} At the same time, more and more evidence shows that tumor-like proliferation and apoptosis defects of FLSs are one of the root causes of RA. Inadequate apoptosis of FLSs can lead to synovium hyperplasia and promote pannus formation, while too many FLSs can increase the release of MMPs and various chemokines, degrade extracellular matrix (ECM), enhance inflammatory response, damage joints and cause inflammatory infiltration. Combined with previous PPI analysis, our current study results suggest that *TNF*, *STAT1*, *PARP1*, *NFKBIA*,




Figure 4 GO functional enrichment analysis represented in bar chart (A), bubble diagram (B) and clustering dendrogram (C). Log FC means fold change of log value.

NFKB1, *MMP3*, *MMP2*, *MMP1*, *MAPK8*, *JAK2*, *IL6*, *IL1B*, *IL8*, *CCL5*, *CASP9*, *CASP3*, *CASP1*, *BAX* and other genes are involved in the anti-inflammatory and proapoptotic activities of GSZD, thus playing a pharmacological role in the treatment of RA. Therefore, we established a cell model of RA in vitro to further explore and study the anti-inflammatory and proapoptotic effects of GSZD.

The Main Potential Active Component Against RA in GSZD

As shown the DTN in Figure 6, 11 chemical components in GSZD can act on multiple similar or different targets at the same time, indicating that GSZD has therapeutic effects on RA through the multi-component and multitarget mechanism. Through in-depth analysis of the network diagram, it is found that GZ-19, GZ-3, GZ-9 and GZ-8 have the most targets, 26, 25, 24, 20, respectively, suggesting that these compounds have made a significant contribution to anti-RA action of GSZD, and these compounds also seem to be able to be used as qualitymarker (Q-marker) components of GSZD for its future quality control (Table 5).

Anti-inflammation is the Important Way for the Anti-RA Effects of GSZD

The results of KEGG suggested that NF- κ B signaling was a key pathway for anti-RA effects of GSZD, and NF- κ B1, NF- κ IA was also considered as the joint target of GSZD. Therefore, the effect of GSZD on nuclear translocation of the NF- κ B was researched using immunofluorescence assay. The results showed that the nuclear translocation of NF- κ B subunit P65 increased sharply in TNF- α -induced cells, and the nuclear transcription of NF- κ B was significantly inhibited when GSZD was added (Figure 7).

In addition, the qRT-PCR was applied to explore the role of GSZD in regulating the expression of inflammation-related genes in TNF- α -induced MH7A cells. As shown in Figure 8A, TNF- α stimulation significantly

BP GO.0032496 Response to lipopolysaccharide THR/PDE-fOINTRAUM/REJIMAPREJUNDIJUNIJA/2116.011.1911.190A/EDNRBM CONTONNI LOBG/CD NTCCL/CSPP/CASPICASPICAS 110AL 1 BP GO.0002237 Response to molecule of bacterial origin TMF/PDE-fOINTRAUM/REJIMAPREJUNDIJUNIJA/2116.011.1911.110A/EDNRBM CONTONNI LOBGE/DTUCCL/CSPP/CASPICASPICAS 110AL 1 BP GO.0001819 Posteve regulation of cytokine production TMF/STK/STATI/PTPR/CHDE4DIN/REJIMAPS/BUL/JIL/JIL/JIL/JIL/JIL/JIL/JIL/JIL/JIL/JI	Count
International Construction COMTIONN INCOMENDATION COMTIONN INCOMENDATION BP GO.0001819 Positive regulation of cytokine production TNFISYKISTAT IIPTPRC/PDE4DINFR811/JAK2IIL71II.61ILL81ILL17AIILL51HS1 BP GO.0007661 Leukocyte proliferation SYK/RPS6/PTPRC/IMPDH2/II/TIL6/ILL81ILS/CSFIRICDRN1AICD86/CD40/CCL BP GO.0007663 Lymphocyte proliferation SYK/RPS6/PTPRC/IMPDH2/II/TIL6/ILL81ILL51/CDKN1AICD86/CD40/CCL5/CASP BP GO.0007664 Lymphocyte proliferation SYK/RPS6/PTPRC/IMPDH2/II/TIL6/ILL81ILS/CDKN1AICD86/CD40/CCL5/CASP BP GO.00071216 Cellular response to biolic stimulus TNFISYK/DE2/DNFKBI/IMPDH2/II/TIL6/ILL8/ILL3/CDKN1AICD86/CD40/CCL5/CASP BP GO.001716 Positive regulation of neuron death TNFIS/FRDE2/DNFKBI/IMPC/IMPDH2/II/TIL6/ILL8/ILL3/CDKN1AICD86/CD40/CCL5/CASP BP GO.01901216 Positive regulation of neuron death TNFIFRE/IMPE3/IJ/NI/KE2/IAXXITM BP GO.0190276 Neuroinflammatory response TNFIFRE/IMPE3/IJ/NI/KE2/IAXXITGS2/IKKB/GEREDNBIC/NRI/CD1/ICASP3/BRC CC GO.0098959 Membrane microdomain TNFIS/CGA3/PTPRC/IAX2/ITGS2/IKKB/GEREDNBIC/NRI/CD1/ICASP3/BRC CC GO.0098959 External side of plasma membrane TNFIS/CGA3/PTPRC/IAX	B/CXCL8/ 22
International DDIT3ICSFIRICD86/CD40/CD14/CASP1/BIRC3/ATT4/APPIABL1 BP GO-0076661 Leukocyte proliferation SYK/RP56/PTRC/IMPDH2/IL/7/IL6/IL18/IL15/CSFIRICDKN1A/CD86/CD40/CCL BCL2/BAX/ATM/ABL1 BP GO-0046651 Lymphocyte proliferation SYK/RP56/PTRC/IMPDH2/IL/7/IL6/IL18/IL15/CDKN1A/CD86/CD40/CCL5/CASP BAX/ATM/ABL1 BP GO-0032343 Monouclear cell proliferation SYK/RP56/PTRC/IMPDH2/IL/7/IL6/IL18/IL15/CDKN1A/CD86/CD40/CCL5/CASP BAX/ATM/ABL1 BP GO-0071216 Cellular response to biod: stimulus TNF/SYK/PDE4D/INFKBAI/MFKB1/MAPK8/IL6/IL18/EDNRB/DDIT3/CXCL8/CD86/ CCL5/CASP1/ABL1 BP GO-1901216 Positive regulation of neuron death TNF/SYK/PDE4D/INFKBAI/MFKB1/MAPK8/IL6/IL18/EDNRB/DDIT3/CXCL8/CD86/ CCL5/CASP1/ABL1 BP GO-0150076 Neuroinflammatory response TNF/THRA/SYK/PRKACB/JAK2/ITGB2/IL6/IL18/EDFR/ATM/APP CC GO-0049871 Membrane raft TNF/SLC6A3/PTPRC/IMA2/ITGB2/IL6/IL18/EDFR/ATM/APP CC GO-0049897 Membrane raft TNF/SLC6A3/PTPRC/IMA2/ITGB2/IL6/IL18/EDFR/ATM/APP CC GO-0049897 Membrane region TNF/SLC6A3/PTPRC/IMA2/ITGB2/IL6/IL18/EDFR/EDNRB/CNR1/CD14/CASP3/BRC CC GO-0049897 Exermal side of plasma membrane TNF/SLC6A3/PTPRC/IMA2/IL6/IL6/IL6/IL6/IL6/I	B/CXCL8/ 22
Image: Constraint of the second se	ISPB1/ 24
Image: An anti-orgen and the second secon	CL5/CASP3/ 18
BAXIATMIABLI BAXIATMIABLI BP GO:0071216 Cellular response to biotic stimulus TNFISYK/PDE4DINFKBIAINFKB1I/MAPKBIIL6/IL1BIEDNRB/DDIT3/CXCLB/CDB/CCLS/CASP1IABLI BP GO:1901216 Positive regulation of neuron death TNFIPARP1 /JUN/ITGB2/F0X03/DDIT3/CASP9/CASP3/BAX/ATMIATF4/ABLI BP GO:048871 Multicellular organismal homeostasis TNFIFHRA/SYK/PRKACBJAK2/IT/IL6/ILL1BILL15/IGF1R/HSPB1/EGFR/EDNRB/DD CC GO:048871 Multicellular organismal homeostasis TNFIFHRA/SYK/PRKACBJAK2/IT/GB2/IL6/ILL1BIEGFR/EDNRB/CNR1/CD14/CASP3/BIRC CC GO:0150076 Neuroinflammatory response TNFI/FIPRC/JMA2/ITGB2/IL6/ILL1BI/EGFR/EDNRB/CNR1/CD14/CASP3/BIRC CC GO:0045121 Membrane raft TNFI/SLC6A3/IPTPRC/JAK2/ITGB2/ILKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRC CC GO:0098857 Membrane microdomain TNFI/SLC6A3/IPTPRC/JAK2/ITGB2/ILKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRC CC GO:0098053 Membrane region TNFI/SLC6A3/IPTPC/JAK2/ITGB2/ILKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRC CC GO:0098053 Nuclear envelope PDE4D/PAR/IPAK1/EGFR/EDNRB/BCL2/BAX/APP/ALOX5/ABLI CC GO:0003126 Nuclear membrane SYK/ITGB2/ITGA/ITGA/IL6/IKAB/BI/GF/IRCD40 CC GO:00031965 Nuclear membrane PDE4D/PAK1/EGFR/EDNRB/BCL2/	SP3/BCL2/ 17
CCL:SICASP1/ABL1 BP GO:1901216 Positive regulation of neuron death TNF/PARP1/JUNI/TGB2/FOXO3/DDIT3/CASP9/CASP3/BAX/ATM/ATF/4/ABL1 BP GO:0048871 Multicellular organismal homeostasis TNF/THRA/SYK/PKACB/JAX/ATM/AIT/L6/IL1B/IL15/IGF1R/HSPB1/EGFR/EDNRB/DL CTSH/CSF1R/CNR1/BCL2/BAX/ATF/4 BP GO:0150076 Neuroinflammatory response TNF/TPRC/MMP3/JUNI/JAX2/ITGB2/IL6/IL1B/EGFR/ATM/APP CC GO:0045121 Membrane raft TNF/SLC6A3/PTPRC/JAK2/ITGB2/IL6/BL/BSE/GFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0098857 Membrane microdomain TNF/SLC6A3/PTPRC/JAK2/ITGB2/ILKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0098869 Membrane region TNF/ISLC6A3/PTPRC/JAK2/ITGB2/ILKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0098897 External side of plasma membrane TNF/IGFBR3/PTPRC/IJAK2/ITGB2/ILKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0009897 External side of plasma membrane SYK/ITGB2/ITCAL/ITGA7/IL/B/KKB/EGFR/EDNRB/CD40/CD14 CC GO:0009802 Plasma membrane receptor complex SYK/ITGB2/ITGAL/ITGA7/IL/B/K/B/B/DAA1/HDAC1/CASP3/APP/ABL1 CC GO:0003165 Nuclear membrane PDE4D/PAK1/EGFR/EDNRB/BC12/ALOXS/ABL1 CC GO:0003165 Nuclear membrane PDE4D/PAK1/EGFR/EDNRB/BC1/ALOXS/ABL1	SP3/BCL2/ 17
BP GO:0048871 Multicellular organismal homeostasis TNF/THAR/SYK/PRKACB/JAK2/II/TIL6/ILI B/ILI 5/IGF IR/HSPB1/EGFR/EDNRB/DL CTSH/CSF IR/CNR / BCL2/BAX/ATF4 BP GO:0150076 Neuroinflammatory response TNF/PTPRC/JMR2/II/GB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0045121 Membrane raft TNF/IPTPRC/JMR2/II/GB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0098577 Membrane microdomain TNF/SLC6A3/PTPRC/JAK2/II/GB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0098589 Membrane region TNF/SLC6A3/PTPRC/JAK2/II/GB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0098589 Membrane region TNF/SLC6A3/PTPRC/JAK2/II/GB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0098589 Membrane region TNF/ISLC6A3/PTPRC/JAK2/II/GB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/B/RC CC GO:0098575 Nuclear envelope PDE4D/PARP1/PRK/I/EGFR/EDNRB/BCL2/BAX/APPIALOXS/ABL1 CC GO:0043025 Neuronal cell body SRDSA1/SLC6A3/PPPSC/PPP1/CA/HSP90AA1/HDAC1/CASP3/APPIABL1 CC GO:0043025 Neuronal cell body SRDSA1/SLC6A3/PPPSC/PP1/CA/HSP90AA1/HDAC1/CASP3/APPIABL1 CC GO:0031965 Nuclear membrane PDE4D/PAK1//EGFR/EDNRB/BCL2/ALOXS/ABL1 CC GO:0031904 Endosome lumen <t< td=""><td>86/CD14/ 16</td></t<>	86/CD14/ 16
CTSH/CSF IR/CNR I/BCL2/BAX/ATF4 BP GO:0150076 Neuroinflammatory response TNF/PTPRC/MMP3/JUNIJAK2/ITGB2/IL6/IL1B/EGFR/ATM/APP CC GO:0045121 Membrane raft TNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRC CC GO:0098557 Membrane microdomain TNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRC CC GO:0098589 Membrane region TNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRC CC GO:0098977 External side of plasma membrane TNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRC CC GO:0005635 Nuclear envelope PDE4D/PARP1/PAK1/EGFR/EDNRB/BCL2/BAX/APP/ALOX5/ABL1 CC GO:0098802 Plasma membrane receptor complex SYK/ITGB2/ITGAL/ITGA7/IL6/IKBKB/IGF1R/CD40 CC GO:0031655 Neuronal cell body SRD5A1/SLC6A3/PPPSC/PPP1CA/HSP90AA1/HDAC1/CASP3/APP/ABL1 CC GO:0031905 Integrin complex ITGB2/ITGAL/ITGA7 CC GO:0008305 Integrin complex ITGB2/ITGAL/ITGA7 CC GO:000126 Cytokine receptor binding TNF/SF10/TNF/IGFBR3/SYK/STAT11/JAK2/IL7/IL6/IL1B/IL15/ILC2/B/CCL5/CASP3 MF GO:0005126 Cytokine activity TNFSF10/TNF/IGFBR3/SYK/STAT11JAK2/	12
CCGO:0045121Membrane raftTNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRCCCGO:0098857Membrane microdomainTNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRCCCGO:0098859Membrane regionTNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRCCCGO:0098897External side of plasma membraneTNF/ISLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRCCCGO:0009897External side of plasma membraneTNF/IGFBR3/PTPRC/ITGB2/ILIR1/IL17A/ECE1/CD86/CD40/CD14CCGO:0005635Nuclear envelopePDE4D/PARP1/PAK1/EGFR/EDNRB/BCL2/BAX/APPIALOX5/ABL1CCGO:0098802Plasma membrane receptor complexSYK/ITGB2/ITGAL/ITGA7/IL6/IIKBKB/IGF1R/CD40CCGO:003105Nuclear membrane receptor complexSYK/ITGB2/ITGAL/ITGA7/IL6/IIKBKB/IGF1R/CD40CCGO:0031965Nuclear membranePDE4D/PAK1/EGFR/EDNRB/BCL2/ALOX5/ABL1CCGO:0031965Integrin complexITGB2/ITGAL/ITGA7CCGO:0008305Integrin complexITGB2/ITGAL/ITGA7CCGO:000126Cytokine receptor bindingTNFSF10/TNF/TGFBR3/SYK/STAT1/JAK2/IL7/IL6/ILLB/ILL1S/CXCLB/CCL5/CASP3MFGO:0042562Hormone bindingTHRA/IGF1R/EGFR/EDNRB/ECE1/CTSH/ARMFGO:0042562Hormone bindingSTAT1/PKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin-like protein ligase bindingSTAT1/IPKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingSTAT1/IPKACB/NFKBIA/JUN/HS	DDIT3/ 20
CCGO:0098857Membrane microdomainTNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRCCCGO:0098589Membrane regionTNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRCCCGO:0009897External side of plasma membraneTNF/TGFBR3/PTPRC/ITGB2/ILI R1 /ILI TA/ECE1/CD86/CD40/CD14CCGO:0005635Nuclear envelopePDE4D/PARP1/PAK1/EGFR/EDNRB/BCL2/BAX/APP/ALOX5/ABL1CCGO:0098802Plasma membrane receptor complexSYK/ITGB2/ITGAL/ITGA7/IL6/IKBKB/IGF1R/CD40CCGO:0043025Neuronal cell bodySRD5A1/SLC6A3/PPPSC/PP1/CA/HSSP0AA1/IHDAC1/CASP3/APP/ABL1CCGO:0031965Nuclear membranePDE4D/PAK1/EGFR/EDNRB/BCL2/ALOX5/ABL1CCGO:0031965Integrin complexITGB2/ITGAL/ITGA7CCGO:0031904Endosome lumenJAK2/CTSH/APPMFGO:0005126Cytokine receptor bindingTNFSF10/TNF/TGFBR3/SYK/STAT1/JAK2/IL7/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:005125Cytokine activityTNFSF10/TNF/IL7/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:0031625Ubiquitin-like protein ligase bindingSTAT1/IPRKACB/NFKBIA/JUN/IHSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingPRKACB/NFKBIA/JUN/IHSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	11
CCCGO:0098589Membrane regionTNF/SLC6A3/PTPRC/JAK2/ITGB2/IKBKB/EGFR/EDNRB/CNR1/CD14/CASP3/BIRCCCGO:0009897External side of plasma membraneTNF/TGFBR3/PTPRC/ITGB2/ILIR1/IL17A/ECE1/CD86/CD40/CD14CCGO:0005635Nuclear envelopePDE4D/PARP1/PAK1/EGFR/EDNRB/BCL2/BAX/APP/AL0X5/ABL1CCGO:0098802Plasma membrane receptor complexSYK/ITGB2/ITGAL/ITGA7/IL6/IKBKB/IGF1R/CD40CCGO:0043025Neuronal cell bodySRD5A1/SLC6A3/PPP5C/PPP1CA/HSP90AA1/HDAC1/CASP3/APP/ABL1CCGO:0031965Nuclear membranePDE4D/PAK1/IEGFR/EDNRB/BCL2/AL0X5/ABL1CCGO:0031965Nuclear membranePDE4D/PAK1/IEGFR/EDNRB/BCL2/AL0X5/ABL1CCGO:001165Nuclear membranePDE4D/PAK1/IEGFR/EDNRB/BCL2/AL0X5/ABL1CCGO:0008305Integrin complexITGB2/ITGAL/ITGA7CCGO:001126Cytokine receptor bindingTNFSF10/TNF/TGFBR3/SYK/STAT1/JAK2/ILT/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:0005126Cytokine receptor bindingTHFA/IGF1R/EGFR/EDNRB/ECE1/CTSH/ARMFGO:0005125Cytokine activityTNFSF10/TNF/IL7/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:0031625Ubiquitin-like protein ligase bindingSTAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingPRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	RC3/APP I3
CCGO:0009897External side of plasma membraneTNF/TGFBR3/PTPRC/ITGB2/ILTR1/IL17A/ECE1/CD86/CD40/CD14CCGO:0005635Nuclear envelopePDE4D/PARP1/PAK1/EGFR/EDNRB/BCL2/BAX/APP/ALOX5/ABL1CCGO:0098802Plasma membrane receptor complexSYK/ITGB2/ITGAL/ITGA7/IL6/IKBKB/IGF1R/CD40CCGO:0043025Neuronal cell bodySRD5A1/SLC6A3/PPP5C/PPP1CA/HSP90AA1/HDAC1/CASP3/APP/ABL1CCGO:0031965Nuclear membranePDE4D/PAK1/EGFR/EDNRB/BCL2/ALOX5/ABL1CCGO:0031965Nuclear membranePDE4D/PAK1/EGFR/EDNRB/BCL2/ALOX5/ABL1CCGO:0031965Integrin complexITGB2/ITGAL/ITGA7CCGO:0031904Endosome lumenJAK2/CTSH/APPMFGO:005126Cytokine receptor bindingTNFSF10/TNF/TGFBR3/SYK/STAT1/JAK2/IL7/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:005125Cytokine activityTNFSF10/TNF/ILGFIR/EDNRB/ECE1/CTSH/ARMFGO:005125Cytokine activitySTAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin-like protein ligase bindingSTAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingPRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	RC3/APP I3
CCCoCoCoCoCCGO:005635Nuclear envelopePDE4D/PARP1/PAK1/EGFR/EDNRB/BCL2/BAX/APP/ALOX5/ABL1CCGO:0098002Plasma membrane receptor complexSYK/ITGB2/ITGAL/ITGA7/IL6/IKBKB/IGF1R/CD40CCGO:0043025Neuronal cell bodySRD5A1/SLC6A3/PPP5C/PPP1CA/HSP90AA1/HDAC1/CASP3/APP/ABL1CCGO:0031965Nuclear membranePDE4D/PAK1/EGFR/EDNRB/BCL2/ALOX5/ABL1CCGO:0031905Integrin complexITGB2/ITGAL/ITGA7CCGO:0031904Endosome lumenJAK2/CTSH/APPMFGO:005125Cytokine receptor bindingTNFSF10/TNF/ITGFBR3/SYK/STAT1/JAK2/ILT/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:005125Cytokine activityTNFSF10/TNF/IILF/ILL1B/IL15/CXCL8/CCL5MFGO:0044389Ubiquitin-like protein ligase bindingSTAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingPRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	RC3/APP I3
CircleInterim ControlSectorCCGO:0098802Plasma membrane receptor complexSYK/ITGB2/ITGA/ITGA/ITGA/ITGA/ITGA/ITGA/ICCGO:0043025Neuronal cell bodySRD5A/ISLC6A3/PPP5C/PPP1CA/HSP90AA1/HDAC1/CASP3/APP/ABL1CCGO:0031965Nuclear membranePDE4D/PAK1/EGFR/EDNRB/BCL2/ALOXS/ABL1CCGO:0008305Integrin complexITGB2/ITGAL/ITGA7CCGO:0031904Endosome lumenJAK2/CTSH/APPMFGO:0005126Cytokine receptor bindingTNFSF10/TNF/TGFBR3/SYK/STAT1/JAK2/ILT/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:0042562Hormone bindingTNFSF10/TNF/ILG/IRLB/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:0043195Ubiquitin-like protein ligase bindingSTAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingPRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingPRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	10
CCGO:0043025Neuronal cell bodySRD5A1/SLC6A3/PPP5C/PPP1CA/HSP90AA1/HDAC1/CASP3/APP/ABL1CCGO:0031965Nuclear membranePDE4D/PAK1/EGFR/EDNRB/BCL2/ALOXS/ABL1CCGO:0008305Integrin complexITGB2/ITGAL/ITGA7CCGO:0031904Endosome lumenJAK2/CTSH/APPMFGO:0005126Cytokine receptor bindingTNFSF10/TNF/ITGFBR3/SYK/STAT1/JAK2/ILT/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:0005125Cytokine activityTNFSF10/TNF/ILGFR/EDNRB/ECE1/CTSH/ARMFGO:0005125Cytokine activityTNFSF10/TNF/IL1/IL6/IL1B/IL17A/IL15/CXCL8/CCL5MFGO:0044389Ubiquitin-like protein ligase bindingSTAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingPRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	10
CCGO:0031965Nuclear membranePDE4D/PAK1/EGFR/EDNRB/BCL2/ALOX5/ABL1CCGO:008305Integrin complexITGB2/ITGAL/ITGA7CCGO:0031904Endosome lumenJAK2/CTSH/APPMFGO:0005126Cytokine receptor bindingTNFSF10/TNF/TGFBR3/SYK/STAT1/JAK2/ILT/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:0005125Cytokine activityTNFSF10/TNF/ILGFR/EDNRB/ECE1/CTSH/ARMFGO:0005125Cytokine activityTNFSF10/TNF/IL1/IL6/IL1B/IL17A/IL15/CXCL8/CCL5MFGO:0044389Ubiquitin-like protein ligase bindingSTAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingPRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	8
ColColColColCCGO:0008305Integrin complexITGB2/ITGAL/ITGA7CCGO:0031904Endosome lumenJAK2/CTSH/APPMFGO:0005126Cytokine receptor bindingTNFSF10/TNF/ITGFBR3/SYK/STAT1/JAK2/ILT/IL6/IL1B/IL15/CXCL8/CCL5/CASP3MFGO:0042562Hormone bindingTHRA/IGF1R/EGFR/EDNRB/ECE1/CTSH/ARMFGO:005125Cytokine activityTNFSF10/TNF/IL7/IL6/IL1B/IL17A/IL15/CXCL8/CCL5MFGO:0044389Ubiquitin-like protein ligase bindingSTAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2MFGO:0031625Ubiquitin protein ligase bindingPRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	9
CC GO:0031904 Endosome lumen JAK2/CTSH/APP MF GO:0005126 Cytokine receptor binding TNFSF10/TNF/TGFBR3/SYK/STAT1/JAK2/IL7/IL6/IL1B/IL1S/CXCL8/CCL5/CASP3 MF GO:0042562 Hormone binding THRA/IGF1R/EGFR/EDNRB/ECE1/CTSH/AR MF GO:0005125 Cytokine activity TNFSF10/TNF/IL1/IL6/IL1B/IL17A/IL1S/CXCL8/CCL5 MF GO:0044389 Ubiquitin-like protein ligase binding STAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2 MF GO:0031625 Ubiquitin protein ligase binding PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	7
MF GO:0005126 Cytokine receptor binding TNFSF10/TNF/IGFBR3/SYK/STAT1/JAK2/ILT/IL6/IL1B/IL15/CXCL8/CCL5/CASP3 MF GO:0042562 Hormone binding THRA/IGF1R/EGFR/EDNRB/ECE1/CTSH/AR MF GO:0005125 Cytokine activity TNFSF10/TNF/ILT/IL6/IL1B/IL17A/IL15/CXCL8/CCL5 MF GO:0044389 Ubiquitin-like protein ligase binding STAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2 MF GO:0031625 Ubiquitin protein ligase binding PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	3
MF GO:0042562 Hormone binding THRA/IGF1R/EGFR/EDNRB/ECE1/CTSH/AR MF GO:0005125 Cytokine activity TNFSF10/TNF/IL7/IL6/IL1B/IL17A/IL15/CXCL8/CCL5 MF GO:0044389 Ubiquitin-like protein ligase binding STAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2 MF GO:0031625 Ubiquitin protein ligase binding PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	3
MF GO:0005125 Cytokine activity TNFSF10/TNF/IL7/IL6/IL1B/IL17A/IL15/CXCL8/CCL5 MF GO:0044389 Ubiquitin-like protein ligase binding STAT1/PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2 MF GO:0031625 Ubiquitin protein ligase binding PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	23 13
MF GO:0044389 Ubiquitin-like protein ligase binding STATT //PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2 MF GO:0031625 Ubiquitin protein ligase binding PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	7
MF GO:0031625 Ubiquitin protein ligase binding PRKACB/NFKBIA/JUN/HSP90AA1/EIF4E2/EGFR/CDKN1A/CD40/BCL2	9
	10
MF GO:0019902 Phosphatase binding SYK/STAT1/SLC6A3/PPP1CA/EGFR/CSF1R/BCL2	9
	7
MF GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific STAT I /PARP I /NFKB I /MYC/JUND/JUN/FOXO3/DDIT3/ATF4/AR	10
MF GO:0004713 Protein tyrosine kinase activity SYK/JAK2/IGF1R/EGFR/CSF1R/ABL1	6
MF GO:0070851 Growth factor receptor binding JAK2/IL7/IL6/IL1R1/IL1B/APP	6

Table 3 GO Enrichment Analysis Results of Overlap	oping Genes (OGs)
---	-------------------

(Continued)

GO	ID	Description	Gene ID	Count
MF	GO:0097153	Cysteine-type endopeptidase activity involved in apoptotic process	CASP9/CASP3/CASP1	3

upregulated the expression of IL-6, IL-1, MMP-1, MMP-2, MMP-3, and CCL5 in MH7A cells, but the upregulation was reversed after GSZD treatment. Interestingly, GSZD can dose-dependently reduce the expression of these inflammatory factors and chemokines.

Furthermore, the expressions of JAK2 and STAT3 in MH7A cells was analyzed by Western blot, and it was found that TNF- α could increase the JAK2 and STAT3 in MH7A cells (Figure 8B). Fortunately, GSZD treatment can reverse this expression abnormality. Although the effect of GSZD on JAK2 expression does not appear to be a dose-dependent inhibition, each dose of GSZD significantly inhibited JAK2 expression. In conclusion, the above results indicate that inhibition

of inflammatory response is an important way for GSZD to treat RA.

Proapoptosis is Another Crucial Way for GSZD to Treat RA

As shown in Figure 9A, compared with normal cells, using GSZD intervention after 24 h, the green fluorescence of MH7A cells increased significantly, suggesting $\Delta \Psi$ loss in cells. At the same time, the promotion effect of GSZD was dose-dependent, indicating that GSZD could dose-dependent ly induce MOMP decline in MH7A cells. Subsequently, flow cytometry was used to detect the apoptosis of cells after GSZD intervention. As shown in Figure 9B, GSZD can induce the apoptosis of MH7A cells in a dose-dependent




Figure 5 KEGG functional enrichment analysis represented in bar chart (A), bubble diagram (B) and clustering dendrogram (C).

ID	Description	Gene ID	Count
hsa04210	Apoptosis	TNFSF I 0/TNF/PARP I /NFKBIA/NFKB I /MAPK8/JUN/IKBKB/GADD45B/DDIT3/CTSH/CASP9/CASP3/BIRC3/ BCL2/BAX/ATM/ATF4	18
hsa04657	IL-17 signaling pathway	TNF/NFKBIA/NFKB1/MMP3/MMP1/MAPK8/JUND/JUN/IL6/IL1B/IL17A/IKBKB/HSP90AA1/CXCL8/CASP3	15
hsa04010	MAPK signaling pathway	TNF/PRKACB/PPP5C/PAK I /NFKB I /MYC/MAPK8/JUND/JUN/IL I R I /IL I B/IKBKB/IGF I R/HSPB I /GADD45B/ EGFR/DUSP I /DDIT3/CSF I R/CD I 4/CASP3/ATF4	22
hsa04064	NF-κB signaling pathway	TNF/SYK/PARP I /NFKBIA/NFKB I /IL I R I /IL I B/IKBKB/GADD45B/CXCL8/CD40/CD I 4/BIRC3/BCL2/ATM	15
hsa05161	Hepatitis B	TNF/STAT I /NFKBIA/NFKB I /MYC/MAPK8/JUN/JAK2/IL6/IKBKB/CXCL8/CDKN I A/CASP9/CASP3/BCL2/BAX/ ATF4	17
hsa05323	Rheumatoid arthritis	TNF/MMP3/MMP1/JUN/ITGB2/ITGAL/IL6/IL1B/IL17A/IL15/CXCL8/CD86/CCL5/ATP6V1D	14
hsa04933	AGE-RAGE signaling pathway in diabetic complications	TNF/STAT I IPIM I INFKB I IMMP2IMAPK8/JUNIJAK2/IL6/IL I B/CXCL8/CASP3/BCL2/BAX	14
hsa04620	Toll-like receptor signaling pathway	TNF/STAT I /NFKBIA/NFKB I /MAPK8/JUN/IL6/IL I B/IKBKB/CXCL8/CD86/CD40/CD14/CCL5	14
hsa05166	Human T cell leukemia virus I infection	TNF/PRKACB/NFKBIA/NFKBI/MYC/MAPK8/JUN/ITGB2/ITGAL/IL6/IL1R1/IL15/IKBKB/CDKN1A/CD40/BAX/ ATM/ATF4	18
hsa05167	Kaposi sarcoma-associated herpesvirus infection	SYK/STAT I /NFKBIA/NFKB I /MYC/MAPK8/JUN/JAK2/IRF9/IL6/IKBKB/CXCL8/CDKN I A/CD86/CASP9/CASP3/ BAXSTAT	17
hsa04668	TNF signaling pathway	TNF/NFKBIA/NFKB1/MMP3/MAPK8/JUN/IL6/IL1B/IL15/IKBKB/CCL5/CASP3/BIRC3/ATF4	14
hsa05145	Toxoplasmosis	TNF/STAT I /NFKBIA/NFKB I /MAPK8/JAK2/IL I ORA/IKBKB/CD40/CASP9/CASP3/BIRC3/BCL2/ALOX5	14
hsa05130	Pathogenic Escherichia coli infection	TNFSF I 0/TNF/PAK I /NFKBIA/NFKB I /MAPK8/JUN/IL6/IL I R I /IL I B/IKBKB/CXCL8/CASP9/CASP3/CASP I / BAX/ABL I	17
hsa05202	Transcriptional misregulation in cancer	NFKB1/MYC/MMP3/IL6/IGF1R/HDAC1/GADD45B/DDIT3/CXCL8/CSF1R/CDKN1A/CD86/CD40/CD14/ BIRC3/BAX/ATM	17
hsa05163	Human cytomegalovirus infection	TNF/PRKACB/NFKBIA/NFKB1/MYC/IL6/IL1R1/IL1B/IL10RA/IKBKB/EGFR/CXCL8/CDKN1A/CCL5/CASP9/ CASP3/BAX/ATF4	18
hsa05134	Legionellosis	TNF/NFKBIA/NFKB1/ITGB2/IL6/IL1B/CXCL8/CD14/CASP9/CASP3/CASP1	П
hsa05164	Influenza A	TNFSF I 0/TNF/STAT I /NFKBIA/NFKB I /JAK2/IRF9/IL6/IL I B/IKBKB/CXCL8/CCL5/CASP9/CASP3/CASP I /BAX	16
hsa04621	NOD-like receptor signaling pathway	TNF/STAT I /NFKBIA/NFKB I /MAPK8/JUN/IRF9/IL6/IL I B/IKBKB/HSP90AA I /CXCL8/CCL5/CASP I /BIRC3/BCL2	16
hsa04625	C-type lectin receptor signaling pathway	TNF/SYK/STAT I /PAK I /NFKBIA/NFKB I /MAPK8/JUN/IRF9/IL6/IL I B/IKBKB/CASP I	13
hsa05120	Epithelial cell signaling in <i>Helicobacter</i> pylori infection	PAK I /NFKBIA/NFKB I /MAPK8/JUN/IKBKB/EGFR/CXCL8/CCL5/CASP3/ATP6V I D	11

Table 4 KEGG Enrichment Ana	alysis Results of	Overlapping	Genes ((OGs)
-----------------------------	-------------------	-------------	---------	-------

manner. Further studies showed that GSZD could affect the expression of apoptosis-related proteins. Briefly, GSZD can induce MMOP loss in MH7A cells and lead to apoptosis by upregulating the expressions of *BAX*, C-caspase-3 and C-caspase-9 and downregulating the expression of Bcl-2 (Figure 10A). In addition, GSZD of 0.4 mg/mL and 0.8 mg/mL can increase the expression of p-JNK1/2 without changing the expression of prototype JNK1/2. Although high dose of GSZD can also increase the expression of prototype

JNK1/2, it has a significant promoting effect on the expression of P-JNK1/2 (Figure 10B).

Discussion

Guizhi-Shaoyao-Zhimu decoction (GSZD) is a classic prescription first recorded in the "Synopsis of the Golden Chamber" and usually used to treat "arthromyodynia", such as RA, osteoarthritis, gout, etc.²⁰ In previous works, it is reported that GSZD can effectively treat RA in vivo




Figure 6 Network analysis of targets and active compounds. The data pairs of active compounds and disease target genes were input into Cytoscape software to construct the drug-target network diagram (DTN).

and in vitro, and the research also revealed that GSZD can affect a lot of cytokines, genes and proteins.^{2,20–22} However, these works only supplied scattered evidence for the mechanisms of this TCM formula. In this paper, our object is to systematically study the overall mechanism of GSZD using integrated approach of bioinformatic analysis combined with experimental verification.

In our present study, we systemically analyzed the chemical compositions of GSZD using the HPLC-QTOF-MS /MS assay, which is a comprehensively used way for component analysis of drugs. In the results, 19 constituents were identified, including six triterpenoid saponins and steroidal saponins, four flavonoids, two diterpenes, two phenylpropanoids, three organic acid and two alkaloids. Subsequently, we investigated the antiproliferative activities of these 19 compounds on MH7A cells, and found that 11 of them had potential antiproliferative activities on MH7A cells with the IC₅₀ values less than 100 μ g/mL. Currently, the online target prediction databases, such as PharmMapper and SwissTarget, become useful tools for investigating the action targets of candidate drugs. The PharmMapper web server could be applied to identify the potential drug targets of candidate drugs via reversed pharmacophore matching, and similarly, the SwissTarget Prediction is an online tool could be used to predict the possible protein targets of candidate drugs based on similarity principle via reverse screening.^{37,38} Then, we imported the chemical structures of the 11 compounds of GSZD into the online target prediction database to predict the potential targets via PharmMapper and SwissTarget Prediction (GSZD compounds target library). Furthermore, the GEO, an open public data platform for the acquisition of various high-throughput experimental data, is also a useful online tool for screening the DEGs between normal people and patients, and these DEGs might be the potential targets for disease therapies.⁵ Therefore, we downloaded the microarray data sets of GZ-6

9

Name Degree Average **Betweenness** Closeness Shortest Centrality Centrality Path Length GZ-19 26 2.333333 0.219068 0.428571 GZ-3 25 2.354839 0.18634 0.424658 GZ-9 0.420814 24 2.376344 0.193014 GZ-8 20 2.462366 0.135117 0.406114 GZ-11 19 2.483871 0.133423 0.402597 GZ-16 17 2.526882 0.109816 0.395745 GZ-14 16 2.548387 0.123297 0.392405 GZ-18 14 2.591398 0.09241 0.385892 GZ-7 14 2.591398 0.103755 0.385892 GZ-13 9 0.071367 2.806452 0.356322

Table 5 Network Topology Parameters of Active Compounds in

 GSZD

GSE55457, GSE1919, GSE55235 from the GEO database to construct the DEGs and collected the reported cytokines, genes and proteins that could be affected by GSZD from previous literature; then we combined these targets as the RA target library. Subsequently, as shown in Figure 3, we analyzed the overlapped targets as the possible targets of GSZD for treating RA.

0.094526

0.359073

2.784946

KEGG (<u>http://www.kegg.jp/</u>) and GO (<u>http://geneontol</u> ogy.org/) are two useful online web tools for analysis of the molecular mechanisms and signaling pathways of drug therapies.^{39,40} Combined with KEGG and GO assays, our results revealed that most of the pathways enriched with GSZD's potential targets were closely related to inflammation and apoptosis, suggesting that inflammation control and apoptosis regulation may be the main approaches for GSZD to treat RA. Interestingly, the present results are in accord with the scattered evidence in previous research. In addition, based on the results of PPI network analysis, the top hub genes were selected according to node degree, which were also closely related to inflammation and apoptosis.

Consequently, we carried out further actual in vitro experiments based on MH7A cells to confirm the virtual bioinformatic analysis. Subsequently, we determined the mRNA expression levels of cytokines and mediums (IL-6, IL-1β, MMP-1, MMP-2, MMP-1 and CCL-5) related to inflammation in TNF- α stimulated MH7A, and the results turned out that GSZD could significantly reduce the levels of these cytokines/ mediums. Current evidence from the literature indicates that the JAK/STAT signaling pathway is involved in inflammatory responses in a non-negligible capacity, and JAK inhibitors are also considered as potential drugs for RA treatment.^{41,42} Our current study found that GSZD significantly inhibited the expression of JAK2 and STAT3, suggesting that the antiinflammatory effect of GSZD is related to the regulation of the JAK/STAT pathway. Furthermore, it is generally recognized that the nuclear transcription of NF-kB contributes significantly to the development of inflammatory responses. Interestingly, the present study also suggested that GSZD significantly reduced the nuclear transcription of NF-KB in cells.

Mitochondrial function is important for the survival of cells, and the decreased mitochondrial membrane potential (MMOP, $\Delta \Psi$) could induce the apoptosis of cells.^{43,44} In addition, the flow cytometry analysis with fluorescent double staining is another important way for




Figure 7 Effect GSZD on nuclear transcription of NF- κ B. Cell morphology was determined by DAPI (blue) and antibody of NF- κ B p65 (Red) under a laser confocal microscope (200×). The arrows represented the NF- κ B in cell nucleus.




Figure 8 Effects of GSZD on the inflammation related genes (A) and proteins (B) in TNF- α stimulated MH7A cells. Data were expressed as mean ±SD (n=3), *p<0.01, vs control.

determining the apoptosis in cells.⁴⁵ The results of this study showed that GSZD could reduce the MOMP in MH7A cells, and increase the level of apoptosis. Furthermore, our results also revealed that GSZD increased the expression level of proapoptotic proteins (Bax, caspase-3 and -9), while it reduced the expression level of anti-apoptotic proteins (Bcl-2). In addition, the MAPK pathway is closely related to the apoptosis of synovial cells of joints, and many drugs can promote the apoptosis of synovial cells of RA by regulating the MAPK pathway to play a role in the treatment of RA.¹ MAPKs mainly include extracellular regulated protein kinases (ERK), P38 and C-Jun N-terminal kinase (JNK). Studies have shown that JNK is the main executor of the MAPK pathway involved in apoptosis.⁴⁶ As is well-known, JNK1/2 is an evolutionarily conserved serine and threonine protein kinase, and only the activated JNK1/2 can play a role in promoting cell apoptosis. Therefore, we investigated the effect of GSZD on the expression of JNK1/2 and phosphorylated JNK1/2 (p-JNK1/2) in synovial cells. The results showed that except for the high dose of GSZD (1.6 mg/mL), the expression of prototype JNK1/2 was promoted to a certain extent, and other doses of GSZD could not change the expression of JNK1/2 in MH7A cells. On the contrary, it was significantly observed that the expression of p-JNK1/2 was increased by different doses of GSZD. Taken together, the in vitro cell




Figure 9 Effect GSZD on the membrane potential and apoptosis of the TNF- α induced MH7A cells. (**A**) After GSZD intervention, the mitochondrial membrane potential (MOMP, $\Delta \Psi$ m) change, the green fluorescence indicates that the MOMP of cell is at a normal level, while red fluorescence indicates that the MOMP of cell is decreased. $\Delta \Psi$ m was measured using a MOMP detection kit (JC-1) and observed using a laser confocal microscopy (100×), (**B**) Apoptosis was measured using flow cytometry staining with annexin V-FITC/PI. Data were expressed as mean ±SD (n=3), *p<0.01, vs normal group.




Figure 10 Effects of GSZD on apoptosis related proteins. (A) Proteins expressions of Bcl-2, Bax, cleaved (C)-caspase-3, and cleaved (C)-caspase-9 by Western blot assay. (B) Protein expressions of JNK and phosphorylation (P) of JNK by Western blot assay. Data were expressed as mean ±SD (n=3), *p<0.01, vs normal group.

experimental results confirmed the bioinformatic analysis above.

In conclusion, induction of apoptosis and suppression of inflammatory reactions in synovial fibroblasts are two important ways for GSZD to treat RA, and the integrated approach based on bioinformatic analysis combined with experimental verification is a feasible way for exploration of the drug targets and pharmacological mechanisms of TCMs and its formulas. However, there are also some limitations in our present study due to the limited time and funds. In the subsequent investigations, more work should be devoted to study the activities and molecular mechanisms of the screened potential active components in the Guizhi-Shaoyao-Zhimu decoction.

Acknowledgment

This work was supported by the Sichuan Science and Technology Program (grant number 2019JDRC0074), National Science and Technology Major Project of the Ministry of Science and Technology of China (grant number 2018ZX09721004-009-002), Xinglin Scholar Discipline Promotion Talent Program of Chengdu University of Traditional Chinese Medicine (no. BSH2018006) and the Sate Key Laboratory of Characteristic Chinese Medicine Resources in Southwest China (grant number 2020XSGG021).

Disclosure

The authors report no conflicts of interest in this work.

References

- Zhang Q, Liu J, Zhang M, et al. Apoptosis induction of fibroblast-like synoviocytes is an important molecular-mechanism for herbal medicine along with its active components in treating rheumatoid arthritis. *Biomolecules*. 2019;9(12):795. doi:10.3390/biom9120795
- Zhang Q, Peng W, Wei S, et al. Guizhi-Shaoyao-Zhimu decoction possesses anti-arthritic effects on type II collagen-induced arthritis in rats via suppression of inflammatory reactions, inhibition of invasion & migration and induction of apoptosis in synovial fibroblasts. *Biomed Pharm.* 2019;118:109367. doi:10.1016/j.biopha.2019.109367

- Long Y, Yang Q, Xiang Y, et al. Nose to brain drug delivery a promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion. *Pharm Res.* 2020;159:104795. doi:10.1016/j.phrs.2020.104795
- Peng W, Wang L, Qiu XH, et al. Therapeutic effects of *Caragana* pruinosa Kom. roots extract on type II collagen-induced arthritis in rats. *J Ethnopharmacol*. 2016;191:1–8. doi:10.1016/j.jep.2016.0 6.028
- Liao ML, Shang HH, Li YZ, et al. An integrated approach to uncover quality marker underlying the effects of Alisma orientale on lipid metabolism, using chemical analysis and network pharmacology. *Phytomedicine*. 2018;45:93–104.
- Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets-update. *Nucleic Acids Res.* 2013;41 (Database issue):D991–D995.
- Miyazawa K, Mori A, Okudaira H. Establishment and characterization of a novel human rheumatoid fibroblast-like synoviocyte line, MH7A, immortalized with SV40 T antigen. *J Biochem.* 1998;6:1153–1162.
- Chen Y, Wang YS, Liu M, Zhou BK, Yang GJ. Diosmetin exhibits anti-proliferative and anti-inflammatory effects on TNF-α-stimulated human rheumatoid arthritis fibroblast-like synoviocytes through regulating the Akt and NF-κB signaling pathways. *Phytother Res.* 2020;6:1310–1319.
- Yang JL, Li YX, Wang LL, Zhang ZC, Li ZZ, LncRNA JQ. H19 aggravates TNF-α-induced inflammatory injury via TAK1 pathway in MH7A cells. *Biofactors*. 2020;5:813–820.
- Wang S-N, Xie G-P, Qin C-H, et al. Aucubin prevents interleukin-1 beta induced inflammation and cartilage matrix degradation via inhibition of NF-κB signaling pathway in rat articular chondrocytes.*Int Immunopharm*. 2015;24(2):408–415. doi:10.1016/j. intimp.2014.12.029
- 11. Gong W-G, Lin J-L, Niu Q-X, et al. Paeoniflorin diminishes ConA-induced IL-8 production in primary human hepatic sinusoidal endothelial cells in the involvement of ERK1/2 and Akt phosphorylation. *Int J Biochem Cell Biol.* 2015;62:93–100. doi:10.1016/j.biocel.2015.02.017
- Hu PF, Chen WP, Bao JP, Wu LD. Paeoniflorin inhibits IL-1βinduced chondrocyte apoptosis by regulating the Bax/Bcl-2/caspase-3 signaling pathway. *Mol Med Rep.* 2018;17:6194–6200.
- Li XY, Wang Y, Wang K, Wu YG. Renal protective effect of Paeoniflorin by inhibition of JAK2/STAT3 signaling pathway in diabetic mice. *Biosci Trends*. 2018;12(2):168–176. doi:10.5582/ bst.2018.01009
- Lima KG, Krause GC, Schuster AD, et al. Gallic acid reduces cell growth by induction of apoptosis and reduction of IL-8 in HepG2 cells. *Biomed Pharm.* 2016;84:1282–1290. doi:10.1016/j.biopha.2016.10.048
- Szandruk M, Merwid-Ląd A, Szeląg A. The impact of mangiferin from Belamcanda chinensis on experimental colitis in rats. *Inflammopharmacology*. 2018;26(2):571–581. doi:10.1007/s10787-017-0337-0
- 16. Tian XH, Liu Y, Liu XL, Gao SJ, Sun XF. Glycyrrhizic acid ammonium salt alleviates Concanavalin A-induced immunological liver injury in mice through the regulation of the balance of immune cells and the inhibition of hepatocyte apoptosis. *Biomed Pharm.* 2019;120:109481. doi:10.1016/j.biopha.2019.109481
- Yu JH, Xiao ZC, Zhao RZ, Lu CJ, Zhang YM. Paeoniflorin suppressed IL-22 via p38 MAPK pathway and exerts anti-psoriatic effect. *Life Sci.* 2017;180:17–22. doi:10.1016/j. lfs.2017.04.019
- Zeng Z, Lin C, Wang S, et al. Suppressive activities of mangiferin on human epithelial ovarian cancer. *Phytomedicine*. 2020;15:76.
- Zhou D, Yang Q, Tian T, et al. Gastroprotective effect of gallic acid against ethanol-induced gastric ulcer in rats: involvement of the Nrf2/ HO-1 signaling and anti-apoptosis role. *Biomed Pharm*. 2020;126:110075. doi:10.1016/j.biopha.2020.110075

- 20. Guo Q, Mao X, Zhang Y, et al. Guizhi-Shaoyao-Zhimu decoction attenuates rheumatoid arthritis partially by reversing inflammation-immune system imbalance. *J Trans Med.* 2016;14 (1):165. doi:10.1186/s12967-016-0921-x
- Chen LY, Liu H, Wang CQ, Duan M, Luo YY, Liu RH. Effect of Guizhi Shaoyao Zhimu Decoction on acute swelling and its inflammatory mediators at different time points. *J Jiangxi Univ TCM*. 2013;25:66–68.
- 22. Wang YH, Fang SB, Li YY, Zhou R. Research on mechanism of Guizhi Shaoyao Zhimu Tang in treatment of gouty arthritis based on Toll-MyD88 signaling pathway. *Chin J Exp Trad Med Formul.* 2016;22:121–126.
- Matsui S, Ogata Y. Effects of miR-223 on expression of IL-1β and IL-6 in human gingival fibroblasts. *J Oral Sci.* 2016;58(1):101–108. doi:10.2334/josnusd.58.101
- 24. Kim S, You D, Jeong Y, et al. Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. *Phytomedicine*. 2018;50:43–49. doi:10.1016/j.phymed.2018.08.004
- Sun HB, Yokota H. Reduction of cytokine-induced expression and activity of MMP-1 and MMP-13 by mechanical strain in MH7A rheumatoid synovial cells. *Matrix Biol.* 2002;21(3):263–270. doi:10.1016/S0945-053X(02)00003-3
- 26. Jiang JX, Ma ZN, Hu XH, Dong NZ, Ruan CG. Real-time PCR analysis of the expression of MT1-MMP/TIMP-2/MMP-2 in human vascular endothelial cell lines with different Origin. *Chin J Hemorh.* 2007;17:7–10.
- 27. Hanabayashi M, Takahashi N, Sobue Y, Hirabara S, Ishiguro N, Kojima T. Hyaluronan oligosaccharides induce MMP-1 and -3 via transcriptional activation of NF-κB and p38 MAPK in rheumatoid synovial fibroblasts. *PLoS One.* 2016;11(8):e0161875. doi:10.1371/ journal.pone.0161875
- 28. Shimada T, Imaizumi T, Shirai K, et al. CCL5 is induced by TLR 3 signaling in HuCCT1 human biliary epithelial cells: possible involvement in the pathogenesis of biliary. *Biomed Res.* 2017;38 (5):269–276. doi:10.2220/biomedres.38.269
- 29. Shabani N, Sheikholeslami S, Paryan M, et al. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients. J Cell Phys. 2020;235(2):1366–1373. doi:10.1002/jcp.29055
- Chen Y, Qian J, Wang B, Sha X. Analysis of components absorbed into plasma of the drug pair of Ramulus Cinnamomi and Paeoniae Radix Alba by UPLC-Q/TOF-MS. *Chin J Mod Appl Pharm.* 2017;34:1707–1711.
- 31. Kim J-H, Ha W-R, Park J-H, et al. Influence of herbal combinations on the extraction efficiencies of chemical compounds from Cinnamomum cassia, Paeonia lactiflora, and Glycyrrhiza uralensis, the herbal components of Gyeji-tang, evaluated by HPLC method. *J Pharm Biomed Analysis*. 2016;129:50–59. doi:10.1016/j.jpba.2016.06.044
- 32. Yan Y, Chai C-Z, Wang D-W, Yue X-Y, Zhu D-N, Yu B-Y. HPLC-DAD-Q-TOF-MS/MS analysis and HPLC quantitation of chemical constituents in traditional Chinese medicinal formula Ge-Gen Decoction. J Pharm Biomed Analysis. 2013;80:192–202. doi:10.1016/j.jpba.2013.03.008
- 33. Shao Y, Yang YP, Li JY, Zhou YJ, Chen L, Shen BBHPLC-Q. TOF-MS/MS analysis of chemical constituents of Fangfeng Shaoyaotang. *Chin J Exp Trad Med Formul.* 2018;24:54–59.
- 34. Xia Y-G, Guo X-D, Liang J, Yang B-Y, Kuang H-X. Screening and identification of steroidal saponins from Anemarrhena asphodeloides employing UPLC tandem triple quadrupole linear ion trap mass spectrometry. *Steroids.* 2017;125:67–80. doi:10.1016/j. steroids.2017.06.011
- 35. Wang Y-H, Avula B, Nanayakkara NP, Zhao J, Khan IA. Cassia cinnamon as a source of coumarin in cinnamon-flavored food and food supplements in the United States. J Agri Food Chem. 2013;61 (18):4470–4476. doi:10.1021/jf4005862

- 36. Abbasi M, Mousavi MJ, Jamalzehi S, et al. Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2019;7:10018–10031.
- Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Res.* 2019;47(W1):W357–W364. doi:10.1093/nar/gkz382
- Wang X, Shen Y, Wang S, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. *Nucleic Acids Res.* 2017;45(W1): W356–W360. doi:10.1093/nar/gkx374
- Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.* 2017;45(D1):D353–D361. doi:10.1093/nar/gkw1092
- 40. Liu W, Liu J, Rajapakse JC. Gene ontology enrichment improves performances of functional similarity of genes. *Sci Rep.* 2018;8 (1):12100. doi:10.1038/s41598-018-30455-0
- 41. Scott DL, Stevenson MD. Treating active rheumatoid arthritis with Janus kinase inhibitors. *Lancet*. 2017;390(10093):431–432. doi:10.1016/S0140-6736(17)31659-8

- Taylor PC, Abdul Azeez M, Kiriakidis S. Filgotinib for the treatment of rheumatoid arthritis, Expert Opin. *Investig Drugs*. 2017;26:1181–1187.
- 43. Sakamuru S, Attene-Ramos MS, Xia M. Mitochondrial membrane potential assay. *Methods Mol Biol*. 2016;1473:17–22.
- 44. Li RL, Zhang Q, Liu J, et al. Hydroxy-α-sanshool possesses protective potentials on H2O2-stimulated PC12 cells by suppression of oxidative stress-induced apoptosis through regulation of PI3K/Akt signal pathway. Oxid Med Cell Longev. 2020;2020:3481758.
- 45. Wang JN, Guo N. Techniques and methods of identifying apoptosis. *Chin J Pharmacol Toxicol*. 2005;19:466–470.
- 46. Wang JZ, Lian JR, Kong XY, Lin N. Effect of triptolide on cell proliferation and regulation of RAS MAPKs pathway in synoviocytes induces by tumor necrosis factor. *Chin J Chin Mater Med.* 2010;35:888–891.

Journal of Inflammation Research

Publish your work in this journal

The Journal of Inflammation Research is an international, peerreviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peerreview system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-inflammation-research-journal

Dovepress